

# JAMIE ROSE KUHAR

(FORMERLY JAMIE ROSE LEVIN)

jamierosekuhar@gmail.com • (202) 270-3778 • 302 18th Ave E., Unit B, Seattle, WA 98112

<http://www.linkedin.com/in/jamierosekuhar/>

---

## Education

---

**University of Washington**, Seattle, WA 9/2010-8/2015

**Ph.D., Pharmacology**

Cumulative GPA: 3.83/4.00

**Molecular Medicine Certificate Program** – 2015 HHMI/UW Molecular Medicine Scholar  
**Technology Entrepreneurship Certificate, Foster School of Business**

**Emory University**, Atlanta, GA 9/2005-5/2009

**Bachelor of Science: Neuroscience and Behavioral Biology; Minor: Japanese**

Major GPA: 3.86/4.00; Cumulative GPA: 3.73/4.00

**Kansai Gaidai University**, Osaka, Japan 8/2007-12/2007

**Study Abroad Program, Japanese Studies**

---

## Professional Experience

---

**Associate, Product Management**, *NanoString Technologies*, Seattle, WA 9/2015-Present

- Plan and manage commercialization of NanoString's novel RNA:Protein product line through cross-functional communication with R&D, sales, and manufacturing
- Analyze the immuno-oncology research market to inform product development guidelines and marketing strategy
- Develop marketing and training materials to promote technology adoption

**Graduate Student Researcher**, *UW Department of Pharmacology*, Seattle, WA 9/2010-9/2015

- Dissertation Topic: Investigated cellular mechanisms of morphine tolerance using cell culture models, biochemistry, and proteomics with the goal of designing new pain medications with reduced side effects
- Mentored and trained 5 undergraduate and post-baccalaureate students in the laboratory
- Managed collaborative projects among 5 scientists from 3 laboratories

**Market Analyst**, *Coulter Translational Research Partnership Program*, Seattle, WA 1/2015-9/2015

- Assessed the market for submitted proposals to inform funding decisions and strategic business plans
- Managed funded teams and oversaw go-to-market strategies by ensuring adherence to Gantt charts, performing continuous market/technology assessments, and identifying potential licensees

**Technology Licensing Fellow**, *CoMotion (Formerly C4C)*, Seattle, WA 7/2013-12/2014

- Analyzed commercial potential of technologies disclosed to CoMotion and presented findings in a weekly written report, which influenced next steps taken by the inventor and UW

**Research Technician**, *Emory University, Department of Pharmacology*, Atlanta, GA 6/2009-8/2010

- Independently designed and executed experiments to investigate the role of specific proteins in learning and memory before and after seizures

**Research Analyst**, *Adjuvant Partners*, Washington, DC 5/2007-8/2007

- Contributed to Adjuvant's core strategic consulting practice by updating its database of worldwide life science companies
- Generated a report used by Adjuvant's CEO on the market potential for a bioagriculture anti-frost drug

---

## Leadership Experience

---

**President; VP Relations, UW Science and Engineering Business Association (SEBA)** 9/2012-9/2015

- Coordinated events and volunteer opportunities to teach business skills to science and engineering students (e.g. SEBA Career Fair [\$100,000 annual revenue] and the Foster Business Plan Competition)
- Promoted and developed relationships between SEBA and the Seattle business community
- Managed 9 person officer team, 24 additional active members, and a \$90,000 budget
- Increased revenue 22%

**Executive Committee Member, UW Molecular Medicine Certificate Program** 5/2012-3/2014

- Planned the development and implementation of the Molecular Medicine Ph.D. program
- Acted as student liaison for the Molecular Medicine Certificate Program

**Committee Chair; External Relations; Marketing Director, UW Bioscience Careers** 6/2011-6/2014

- Coordinated monthly seminars featuring professionals with Ph.D.s in nonacademic careers to expose graduate students and post-doctoral fellows to career options
- Managed a \$10,000 budget and 12 person committee responsible for operating the seminar series
- Increased seminar attendance 21%
- Increased funding 10%

---

## Additional Experience

---

**Volunteer, Life Science Strategy Project, Washington State Department of Commerce,** 9/2014-Present  
Seattle, WA

**Committee Member, Commercialization Committee, Washington Biotechnology & Biomedical Association,** 9/2014-9/2015  
Seattle, WA

**Committee Member, Steering Committee, Life Science Innovation Northwest,** 9/2014-7/2015  
Seattle, WA

**Teaching Assistant, General Pharmacology, UW School of Medicine,** 9/2011-3/2012  
Seattle, WA

**Research Assistant, Yerkes National Primate Research Center,** 5/2008-8/2008  
Atlanta, GA

**Teaching Assistant, Introduction to Biology Laboratory, Emory University,** 1/2007-5/2007  
Atlanta, GA

---

## Selected Publications

---

**Kuhar JR**, Bedini A, Melief EJ, Chiu YC, Striegel HN, Chavkin C (2015). Mu Opioid Receptor Stimulation Activates c-Jun N-Terminal Kinase 2 by Distinct Arrestin-Dependent and Independent Mechanisms. *Cellular Signaling*. 27(9): 1799-1806.

Schattauer S, Miyataki M, Shankar H, Zietz C, **Levin JR**, Liu-Chen LY, Gurevich VV, Rieder MJ, Chavkin C (2012). Ligand Directed Signaling Differences Between Rodent and Human Kappa Opioid Receptors. *JBC*. 287(50): 41595-607.

**Levin JR\***, Serrano G\*, Dingledine R (2012). Reduction in delayed mortality and subtle improvement in retrograde memory performance in pilocarpine-treated mice with conditional neuronal deletion of cyclooxygenase-2 gene. *Epilepsia*. 53(8): 1411-20. \*co-first author

❖ Full list of presentations and publications available upon request